These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33306247)

  • 1. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
    Fabbiani M; Lombardi A; Colaneri M; Del Poggio P; Perini P; D'Ambrosio R; Degasperi E; Dibenedetto C; Giorgini A; Pasulo L; Maggiolo F; Castelli F; Brambilla P; Spinelli O; Re T; Lleo A; Rumi M; Uberti-Foppa C; Soria A; Aghemo A; Lampertico P; Baiguera C; Schiavini M; Fagiuoli S; Bruno R;
    J Viral Hepat; 2021 Mar; 28(3):558-568. PubMed ID: 33306247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
    Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
    J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
    Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
    Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
    Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
    Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.
    D'Ambrosio R; Pasulo L; Puoti M; Vinci M; Schiavini M; Lazzaroni S; Soria A; Gatti F; Menzaghi B; Aghemo A; Capelli F; Rumi MG; Morini L; Giorgini A; Pigozzi MG; Rossini A; Maggiolo F; Pan A; Memoli M; Spinelli O; Del Poggio P; Saladino V; Spinetti A; De Bona A; Capretti A; Uberti-Foppa C; Bonfanti P; Terreni N; Menozzi F; Colombo AE; Giglio O; Centenaro R; Borghi M; Baiguera C; Picciotto V; Landonio S; Gori A; Magnani C; Noventa F; Paolucci S; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Mar; 70(3):379-387. PubMed ID: 30472321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
    Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
    World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
    Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
    J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection.
    Gupta S; Rout G; Patel AH; Mahanta M; Kalra N; Sahu P; Sethia R; Agarwal A; Ranjan G; Kedia S; Acharya SK; Nayak B; Shalimar
    J Viral Hepat; 2018 Jul; 25(7):771-778. PubMed ID: 29377464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis.
    Persico M; Rosato V; Aglitti A; Precone D; Corrado M; De Luna A; Morisco F; Camera S; Federico A; Dallio M; Claar E; Caporaso N; Masarone M
    Antivir Ther; 2018; 23(2):129-138. PubMed ID: 28799522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
    Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H
    J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort.
    Ridruejo E; Piñero F; Mendizabal M; Cheinquer H; Wolff FH; Anders M; Reggiardo V; Ameigeiras B; Palazzo A; Alonso C; Schinoni MI; Zuain MGV; Tanno F; Figueroa S; Santos L; Peralta M; Soza A; Vistarini C; Adrover R; Fernández N; Perez D; Hernández N; Estepo C; Bruno A; Descalzi V; Sixto M; Borzi S; Cocozzella D; Zerega A; de Araujo A; Varón A; Silva M;
    J Med Virol; 2020 Dec; 92(12):3545-3555. PubMed ID: 32749710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort.
    Benhammou JN; Dong TS; May FP; Kawamoto J; Dixit R; Jackson S; Dixit V; Bhattacharya D; Han SB; Pisegna JR
    Pharmacol Res Perspect; 2018 Apr; 6(2):e00379. PubMed ID: 29484189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
    Ottman AA; Townsend ML; Hashem MG; Britt RB
    Ann Pharmacother; 2019 Jun; 53(6):581-587. PubMed ID: 30654625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis.
    Gheorghe L; Iacob S; Curescu M; Brisc C; Cijevschi C; Caruntu F; Stanciu C; Simionov I; Sporea I; Gheorghe C; Iacob R; Arama V; Sirli R; Trifan A
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):275-281. PubMed ID: 28922440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
    Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
    World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.